Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations
Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations
Not yet recruiting · NCT07819838 · Registry updated 2026-09-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations | Recurrent Childhood Malignant Solid Neoplasm; Recurrent Childhood Neuroblastoma; Recurrent Childhood Rhabdomyosarcoma; Refractory Childhood Malignant Solid Neoplasm; Refractory Childhood Neuroblastoma; Refractory Childhood Rhabdomyosarcoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-15 | NCT07819838 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Children's Oncology Group | 79 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||